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Introduction {#sec005}
============

Human immunodeficiency virus (HIV) infection is a major public health problem in sub-Saharan Africa, where it is estimated to live 2/3 of the 34 million people globally infected with HIV \[[@pone.0181836.ref001]\]. In the last decade, coinfection with hepatitis B virus (HBV) became a serious concern among HIV-infected patients, because both viruses share similar routes of infection. In addition, data from Western cohorts show that HIV impacts on almost every aspect of the natural history of HBV infection \[[@pone.0181836.ref002], [@pone.0181836.ref003]\]. Among the worldwide HIV-infected individuals, 5--15% are estimated to be coinfected with HBV \[[@pone.0181836.ref002], [@pone.0181836.ref004]--[@pone.0181836.ref006]\]. Consequences include higher rates of chronicity after acute HBV infection, higher level of HBV replication, more rapid progression of liver disease, higher liver-related mortality, and increased risk of hepatotoxicity to antiretroviral drugs \[[@pone.0181836.ref007]--[@pone.0181836.ref012]\]. Also in Western cohorts, liver disease has emerged as a leading cause of death in HIV-infected individuals coinfected with either hepatitis B or C \[[@pone.0181836.ref012]--[@pone.0181836.ref015]\]. Recent studies found that coinfection with HBV can also lead to increased progression in outcomes related to Acquired Immune Deficiency Syndrome (AIDS) and all-cause mortality among HIV-infected patients \[[@pone.0181836.ref016], [@pone.0181836.ref017]\]. Moreover, the burden of coinfection is greater in limited resources regions, such as the sub-Saharan Africa \[[@pone.0181836.ref002], [@pone.0181836.ref004]--[@pone.0181836.ref006]\]. Recently, HIV/HBV coinfection in sub-Saharan Africa has received medical attention, as almost all African countries are scaling up their antiretroviral (ARV) therapy (ART) programs towards the ambitious target of universal coverage and elimination of HIV transmission \[[@pone.0181836.ref018]--[@pone.0181836.ref020]\]. Despite the World Health Organization (WHO) recommendations to test hepatitis B surface antigen (HBsAg) in all HIV-infected patients \[[@pone.0181836.ref021]\], this testing is rarely performed in sub-Saharan Africa, due to its unavailability. Additionally, based on WHO guidelines, patients with HIV/HBV coinfection should start ART regimen with at least two active drugs for HBV infection, such as tenofovir (TDF) with emtricitabine (FTC) or lamivudine (3TC). As a result of the rapid growth of ART programs in sub-Saharan Africa and of the unknown status for HBV infection, when the therapy starts, a general concern has been raised about HBV mutations causing 3TC-resistance \[[@pone.0181836.ref022]--[@pone.0181836.ref024]\]. In spite of this, data regarding the primary resistance of HBV to 3TC in Southern African countries is still insufficient. For instance, Mozambique has the eighth highest HIV prevalence in the world and the prevalence of HIV/HBV coinfection is 13.6% \[[@pone.0181836.ref001], [@pone.0181836.ref025]--[@pone.0181836.ref027]\]. In this country, 3TC and TDF are currently available in the national program for HIV treatment and are recommended in HIV/HBV coinfected patients. However, no national guidelines for screening and treatment of HBV infection are available and liver disease monitoring is not performed routinely, within the national health system.

A recent study conducted in a district of northern Mozambique reported a low rate of resistance to 3TC on HIV/HBV coinfected patients initiating ART; however, data on this matter are not available for the rest of the country. In the southern region of Mozambique, HIV epidemic is worse. Thus, intervention on HBV primary resistance to 3TC among ART naïve HIV-infected patients is needed, since the test-start approach to control this epidemic has been recently launched in the country \[[@pone.0181836.ref028], [@pone.0181836.ref029]\].

Data on HBV genetic diversity is also crucial for disease management, considering that different HBV genotypes might influence the response to antiviral therapy and the clinical outcomes \[[@pone.0181836.ref030]--[@pone.0181836.ref032]\].

In this context, this study aimed to determine the prevalence, genetic diversity and the profile of HBV primary resistance to 3TC among ART naïve HIV-infected patients, attending outpatient clinics in Maputo city, Mozambique.

Methods {#sec006}
=======

Between May and November 2012, a cross-sectional study was conducted in two health centers from the suburban area of Maputo city, Mozambique. Both sites provide primary health care services to HIV-infected individuals in outpatient settings. This local belongs to a large suburban area of Maputo city known for its poverty and high population density, associated with precarious housing, low literacy and income (informal labor) and poor sanitation.

This study was approved by the National Bioethics Committee of Mozambique. ART naïve HIV-infected patients aged \> 18 years were consecutively enrolled after signing the informed consent form. Participants were recruited from a cohort of pre-ART HIV-infected patients followed at the two sites: the Mavalane Health Center and the Polana Caniço Health Center. Pregnant women were not included in this study. For laboratory analysis, a total of 10mL of whole blood was collected from each participant. Sociodemographic characteristics, clinical and laboratory data were recorded in a standardized form. Patients were stratified according to HBsAg serological results: HIV-infected/HBsAg negative patients (mono-infected) and HIV-infected/HBsAg positive patients (coinfected).

All participants performed a complete blood count (Sysmex KX21N: Sysmex Corporation, Sysmex), serum transaminases assays (ABX pentra 400: Horiba ABX SAS, France) and CD4+ T cells count (BD FACSCalibur, CA, USA). First, patients were screened for HBsAg (Diasorin S.p.A., Sallugia, Italy). The ones with positive HBsAg were measured for HBV DNA viral load with COBAS AmpliPrep/COBAS TaqMan HBV test (version 2.0, Roche Diagnostics, Germany; detectability cut-off: 20 IU/mL), which is a fully-automated system that employs real time PCR technology. Briefly, this system uses a set of primers to amplify a highly-conserved pre-Core/Core region of the HBV genome in all eight genotypes (A-H). The protocol for amplification is pre-programmed into the COBAS AmpliPrep/COBAS TaqMan auto analyzer.

HBV genotyping and assessment of HBV drug resistance mutations to 3TC were performed using TRUGENE HBV Genotyping Kit Module 2.0 and the OpenGene DNA sequencing system (Siemens Healthcare Diagnostics Inc, Tarrytown, USA). This device is a fully automated and integrated system that amplifies a fragment of approximately 1.2 Kb, corresponding to a portion of the surface antigen (S) (s101-s237) and the overlapping reverse transcriptase (RT) gene (rt99-rt280). Sequencing of the amplified products was performed using the CLIP^TM^ sequencing technology (Visible Genetics), as previously described \[[@pone.0181836.ref033]\]. Detection of the DNA mutations' profile, responsible for the resistance to 3TC, was based on the phylogenetic analysis of the sequenced fragment. For this purpose, a library of validated and known reference HBV mutants' sequences (consensus sequences) was used. The analysis was performed using GeneObjects^TM^ and GeneLibrarian^TM^ module of the OpenGene DNA Sequencing System, as previously described \[[@pone.0181836.ref034]\]. Genotyping was performed in all samples considering HBV DNA ≥ 300 UI/mL.

For liver disease staging, AST (aspartate aminotransferase), ALT (alanine aminotransferase) and platelet count measurements allowed calculation of FIB-4 (Fibrosis 4 index) and APRI (AST-Platelet Ratio Index). These non-invasive tests were assessed using the formula described elsewhere \[[@pone.0181836.ref035]\]. According to WHO guidelines, an APRI score \> 2.0 indicates significant liver fibrosis and cirrhosis, while a FIB-4 score \> 3.25 indicates significant cirrhosis \[[@pone.0181836.ref036]\].

The sample size was calculated using One-sample test for proportions considering a HBV prevalence of 10.6%, a precision of 3% and a confidence interval (CI) level of 95%. Data were double entered in a secure and de-identified database developed using Microsoft Access™ 2007. Analysis was performed using the statistics package STATA 12.0 (StataCorp, College Station, TX, USA). For univariate analysis, the Mann-Whitney U test was used to compare numerical variables and Pearson's chi-squared test was used to compare categorical variables. Statistical significance was considered when p-value was \< 0.05.

Results {#sec007}
=======

In this study, 518 ART-naïve HIV-infected patients were enrolled. The median age of the study population was 33 years old (interquartile range \[IQR\]: 28--42 years) and 66.8% were women. HBsAg was reactive in 47 patients, yielding a coinfection rate of 9.1%.

Overall, 4 (\<1%) patients reported previous HBV immunization, 56 (10.8%) reported blood transfusion, while 219 (42.3%) and 78 (15.1%) reported ritual scarification and tattoo/piercings, respectively.

[Table 1](#pone.0181836.t001){ref-type="table"} presents the sociodemographic and clinical results according to a stratification by mono-infected or HIV/HBV coinfected patients. There were no significant differences between the HIV monoinfected group and the HIV/HBV coinfected group in terms of age, sex, sexual behavior, exposure to blood (ritual scarification and tattoo/piercings), HBV vaccination and alcohol consumption. However, history of blood transfusion was higher in monoinfected than in coinfected patients (17.7% *versus* 2.2%; p = 0.047). It is worth noting that both groups reported high-risk behaviors, such as high frequency of unprotected sexual intercourse (36.4% in monoinfected *versus* 48.9% in coinfected patients; p = 0.09), as well as multiple sexual partners (80.9% in monoinfected *versus* 83.0% in coinfected patients; p = 0.723). Ritual scarification was also frequent in both groups (42.9% *versus* 41.3% in mono-infected and coinfected patients, respectively; p = 0.833).

10.1371/journal.pone.0181836.t001

###### Comparison of sociodemographic, risk factors and clinical characteristics between mono-infected and coinfected participants.

![](pone.0181836.t001){#pone.0181836.t001g}

  Characteristics                      HIV +         HIV +/HBsAg +   *p-value*
  ------------------------------------ ------------- --------------- -----------
  **Median age, years (IQR)**          33 (28--42)   32 (28--42)     0.581
  **Gender**                                                         
      Male (%)                         155 (33.2)    15 (33.3)       
      Female (%)                       312 (66.8)    30 (66.7)       0.944
  **Multiple partners**                                              
      Yes (%)                          380 (80.9)    39 (83.0)       
      No (%)                           90 (19.1)     8 (17.0)        0.723
  **Unprotected sexual intercourse**                                 
      Yes (%)                          171 (36.4)    23 (48.9)       
      No (%)                           299 (63.6)    24 (51.1)       0.090
  **Scarification**                                                  
      Yes (%)                          200 (42.9)    19 (41.3)       
      No (%)                           266 (57.1)    27 (58.9)       0.833
  **Tattoo/piercings**                                               
      Yes (%)                          73 (15.6)     5 (11.4)        
      No (%)                           395 (84.4)    39 (88.6)       0.455
  **Blood transfusion**                                              
      Yes (%)                          55 (11.7)     1 (2.2)         
      No (%)                           415 (88.3)    45 (97.8)       **0.047**
  **Prior HBV vaccination**                                          
      Yes (%)                          3 (0.6)       1 (2.2)         
      No (%)                           466 (99.4)    45 (97.8)       0.258
  **Alcohol consumption**                                            
      Yes (%)                          176 (37.5)    19 (40.4)       
      No (%)                           294 (62.5)    28 (59.6)       0.688

Furthermore, 2/3 of the patients were classified as HIV stage I and stage II (WHO staging system), with similar distribution among both groups ([Table 2](#pone.0181836.t002){ref-type="table"}). Mono- and coinfected subjects had similar hemoglobin level, leukocytes, lymphocytes, platelets, CD4+T cell counts, and serum transaminase levels. Clinical signs of liver disease (e.g., jaundice, ascites, splenomegaly and hepatomegaly) were not observed in either groups (data not shown).

10.1371/journal.pone.0181836.t002

###### Comparison of laboratory characteristics between coinfected and mono-infected patients.

![](pone.0181836.t002){#pone.0181836.t002g}

  Characteristics                                                     HIV +               HIV+/HBsAg +          p-value
  ------------------------------------------------------------------- ------------------- --------------------- ---------
  **WHO Clinical Stage**                                                                                        
      Stage I (%)                                                     210 (45.5)          22 (46.8)             
      Stage II (%)                                                    138 (29.9)          14 (29.8)             
      Stage III (%)                                                   109 (23.6)          10 (21.3)             
      Stage IV (%)                                                    4 (0.9)             1 (2.1)               0.848
  **Median hemoglobin, g/dL (IQR)**                                   11.6 (10.2--13.0)   12.1 (11.0--12.8)     0.288
  **Median leucocyte count, 10**^**9**^**/L (IQR)**                   4.7 (3.8--5.8)      4.5 (3.6--5.2)        0.177
  **Median lymphocyte count, 10**^**9**^**/L (IQR)**                  2.0 (1.0--2.0)      2.0 (1.0--2.0)        0.186
  **Median platelets count (IQR)**                                    226 (177--269)      212 (176--286)        0.278
  **Median CD4**^**+**^**T--cell count, cells/mm**^**3**^ **(IQR)**   363 (204--508)      327 (131--462)        0.203
  **Median ALT, IU (IQR)**                                            21.4 (16.0--30.1)   26.2 (18.0--35.0)     0.054
  **Median AST (IQR)**                                                28.8 (22.1--38.1)   29.4 (26.0--39.8)     0.244
  **Median HBV DNA, IU/mL (IQR)**                                                         1484 (244--727,292)   
  **HBV DNA categories (IU/mL)**                                                                                
      \< 20                                                           \-                  10 (21.7)             
      ≥ 20 - \< 20 000                                                                    24 (52.2)             
      ≥20 000                                                                             12 (26.1)             
  **Median APRI (IQR)**                                               0.3 (0.2--0.5)      0.4 (0.3--0.5)        0.117
  **APRI scores**                                                                                               
      **\< = 2.0**                                                    460 (98.3)          45 (95.7)             
      **\>2.0**                                                       8 (1.7)             2 (4.3)               0.228
  **Median FIB-4 (IQR)**                                                                                        
  **FIB-4 scores**                                                    0.8 (0.6--1.2)      0.9 (0.7--1.3)        0.231
      **\< = 3.25**                                                   458 (98.7)          44 (95.6)             
      **\>3.25**                                                      6 (1.3)             2 (4.4)               0.112

APRI---aminotransferase-to-platelet ratio index; DNA--desoxirribonucleic acid; IU--International Units; HBV--hepatitis B virus; HIV--human immunodeficiency virus; FIB-4---fibrosis index based on the four factors; IQR = interquartile range; \< 20 IU/mL (undetectable).

Plasma HBV-DNA determination was performed in 46 of the 47 coinfected participants, of whom 10 (21.7%) had undetectable HBV DNA levels (\<20 IU/mL). Among samples with detectable levels of HBV, 24 (52.2%) patients had HBV DNA levels between 20 IU/mL and 20 000 IU/mL and 12 (26.1%) patients had ≥ 20 000 IU/mL ([Table 2](#pone.0181836.t002){ref-type="table"}). Results of hepatic fibrosis assessed by APRI and FIB-4 showed that coinfected and monoinfected patients had similar median values of APRI (0.4 coinfected versus 0.3 in monoinfected) and FIB-4 (0.9 in coinfected versus 0.8 in monoinfected). Also, the frequency of patients with APRI score \>2 (4.3% in coinfected *versus* 1.7% in monoinfected patients), and FIB-4 score \> 3.25 (4.4% in coinfected *versus* 1.3% in monoinfected) was not statistically different.

Genotyping testing for HBV was performed in 27 patients. One sample with HBV-DNA \> 300 IU/mL was not typeable due to its poor quality as shown in [Fig 1](#pone.0181836.g001){ref-type="fig"}. Genotype A was detected in 25 (92.6%) and genotype E was detected in 2 (7.4%) coinfected patients. No 3TC-resistance associated with HBV mutations were detected in any of the tested samples.

![Flowchart of participant's recruitment and testing.\
The flow chart depicts the naïve HIV-infected patients enrolled in the study from two health centers in Maputo, between May and November 2012. Abbreviations: ARV--antiretroviral treatment; HBV VL--Hepatitis B viral load.](pone.0181836.g001){#pone.0181836.g001}

Discussion {#sec008}
==========

To the best of our knowledge, this represents the first study addressing clinical and laboratory characteristics of HIV/HBV coinfection, HBV DNA viral load, and profile of HBV resistance to 3TC in southern Mozambique. The burden of HIV-infection in this region is the heaviest over the country. The prevalence of coinfection was determined to be 9.1%, which was slightly lower than previously reported in the region \[[@pone.0181836.ref025], [@pone.0181836.ref027]\]. However, the obtained prevalence in southern Mozambique was superior to the values reported in the northern region \[[@pone.0181836.ref028]\], and in other countries from sub-Saharan Africa \[[@pone.0181836.ref024], [@pone.0181836.ref037]--[@pone.0181836.ref039]\]. Mozambique is estimated to have more than 1.5 million people living with HIV infection \[[@pone.0181836.ref001], [@pone.0181836.ref026]\]. Based on the current literature and in our study, we anticipate that approximately 150,000 people might be coinfected with HIV/ HBV. Thus, intervening in those cases is a major concern, as coinfected patients are at higher risk of developing liver toxicity to ART, cirrhosis, hepatocelular carcinoma (HCC) and death \[[@pone.0181836.ref040], [@pone.0181836.ref041]\]. In this study, we quantified HBV DNA levels in plasma of HIV/HBV coinfected patients, since this parameter is considered a strong predictor of liver-related diseases (e.g., cirrhosis and HCC) \[[@pone.0181836.ref012], [@pone.0181836.ref042], [@pone.0181836.ref043]\]. Indeed, our data showed that 26.1% of the coinfected patients had a HBV viral load \>20,000 UI/mL. This finding is in line with what was found in another study conducted in developing countries, where a significant proportion of HIV/HBV coinfected patients present HBV DNA≥ 20,000 IU/mL \[[@pone.0181836.ref044]\].

We also assessed APRI and FIB-4 scores, the two most widely studied non-invasive instruments for assessing liver fibrosis in patients with Hepatitis B and C, in absence of liver biopsy or imaging resources, such as ultrasound or fibroscan \[[@pone.0181836.ref045]\]. According to our measurement, APRI and FIB-4 scores were not significantly different in coinfected and monoinfected patients. This can be explained by the fact that in this study, most participants were immunocompetent. Indeed, previous studies have shown that coinfected patients are at higher risk of developing liver fibrosis and cirrhosis \[[@pone.0181836.ref046]\]. As management of HIV/HBV coinfection in sub-Saharan Africa region is hindered by commonly unavailable HBsAg screening and DNA testing in routine care, most HIV infected patients are treated with ART before detection of HBV infection \[[@pone.0181836.ref022], [@pone.0181836.ref024]\]. Therefore, routine HBsAg screening should be implemented in Mozambique and in other countries from this region, where both virus are endemic, to ensure that all coinfected patients are treated with regimens containing TDF plus 3TC or FTC. 3TC is a backbone option of first line ART regimen, globally recommended and recognized as well tolerated and active against both HIV and HBV \[[@pone.0181836.ref047]\]. Prior studies have shown that coinfected people with lower HBV DNA levels (\<20,000 IU/mL) or who are HBeAg-negative, can be considered for 3TC monotherapy, when TDF is not readily available or is contraindicated \[[@pone.0181836.ref044]\] Briefly, no genetic mutations related to HBV resistance to 3TC were found in the S Ag nor in RT genes. In contrast to our finding, recent studies conducted in northern Mozambique and in other sub-Saharan countries found mutations associated with primary HBV resistance to 3TC \[[@pone.0181836.ref028], [@pone.0181836.ref048]\]. While our results suggest that 3TC resistance in southern Mozambique might be very low, previous studies show that for ARV experienced patients, 3TC-resistance emerged in coinfected patients, after 12--24 months of treatment \[[@pone.0181836.ref039], [@pone.0181836.ref049], [@pone.0181836.ref050]\]. Thus, this observation emphasizes that surveillance of HBV resistance profile among ART experienced patients might be critical to improve the national algorithms for HBV treatment.

In this study, genotype A was present in 92.6% of the HBV tested samples. Similar findings were also reported among blood donors in Maputo city during 2004 \[[@pone.0181836.ref051]\], and among HIV-infected adults in northern Mozambique \[[@pone.0181836.ref028]\]. Surprisingly, we found that none of the coinfected patients presented signs of decompensated liver disease (e.g., jaundice, ascites, splenomegaly and hepatomegaly). In contrast, other studies have shown that coinfection was associated with higher risk of cirrhosis, HCC, liver decompensation and death, particularly in those with low CD4^+^ T cell counts \[[@pone.0181836.ref040]\]. This difference might be expected since 75% of the patients included in our study were classified as stage I/II for HIV infection and showed a relatively intact immune system (median CD4+T cell count: 327 cells/mm^3^).

Regarding the impact of HBV on HIV disease progression, previous studies did not find evidence that HBV might accelerate or aggravate the natural history of HIV-infection \[[@pone.0181836.ref052]\]. Indeed, our data showed that CD4+T cell counts were similar in coinfected and mono-infected patients. However, due to the cross-sectional design of our study, we could not conclude about the impact of HBV on HIV disease progression. To answer this question, well-designed prospective studies are needed.

The present study has some limitations. Firstly, the cross-sectional design did not allow to assess the longitudinal impact of HIV/HBV coinfection in the progression to AIDS. Secondly, because TRUGENE is a fully automated and closed system, we could not draw the phylogenetic tree for HBV sequenced fragments. Lastly, due to the relatively small size of the coinfected group, several differences between coinfected and monoinfected groups might not have reached statistical significance.

Conclusions {#sec009}
===========

This study strengthens the knowledge on HIV/HBV coinfection in Mozambique and also allowed to characterize this new cohort in Maputo City. We found that one third of HIV/HBV coinfected patients presents high levels of HBV DNA and are at risk of developing a liver-related disease. This finding raises a serious public health concern, which highlights the need to identify HIV/HBV coinfection in these populations. Finally, this study reinforces the importance of integrating HBV screening programs into HIV routine care to reduce morbidity and mortality levels caused by HIV/HBV coinfection.
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